Literature DB >> 8320171

Inhibitory effects of sizofiran on anticancer agent- or X-ray-induced sister chromatid exchanges and mitotic block in murine bone marrow cells.

Z B Yang1, Y Tsuchiya, T Arika, M Hosokawa.   

Abstract

The inhibitory effects of a biological response modifier (BRM), sizofiran, on sister chromatid exchanges (SCEs) in the bone marrow cells of mice treated with various anticancer agents or irradiation were investigated. Sizofiran (10 mg/kg i.m.) inhibited SCEs induced by mitomycin C (2 mg/kg i.v.), adriamycin (20 mg/kg i.v.) and cyclophosphamide (20 mg/kg i.v.) by about 20%, respectively. Analysis of the SCEs in vivo after irradiation plus sizofiran indicated that SCE levels were significantly lower than those observed in mice exposed to irradiation without sizofiran. Moreover, the effects of sizofiran were dependent on the timing of administration. Our results indicated that sizofiran should be administered simultaneously or soon after irradiation in order to minimize damage. Sizofiran also markedly restored the bone marrow cell mitosis which had been suppressed by anticancer agents, and this action was closely correlated with the prevention of increase in SCEs. These results indicate that in addition to immunopotentiating activity, sizofiran may play a role in preventing chromosomal damage induced by cancer chemotherapy and radiotherapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8320171      PMCID: PMC5919181          DOI: 10.1111/j.1349-7006.1993.tb00173.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  19 in total

1.  Correlation between the antitumor activity of a polysaccharide schizophyllan and its triple-helical conformation in dilute aqueous solution.

Authors:  T Yanaki; W Ito; K Tabata; T Kojima; T Norisuye; N Takano; H Fujita
Journal:  Biophys Chem       Date:  1983-06       Impact factor: 2.352

2.  In vivo persistence of sister chromatid exchanges (SCE) induced by gamma rays in mouse bone marrow cells.

Authors:  P Morales-Ramírez; T Vallarino-Kelly; R Rodríguez-Reyes
Journal:  Environ Mutagen       Date:  1984

3.  Combination therapy of radiation and Sizofiran (SPG) on the tumor growth and metastasis on squamous-cell carcinoma NR-S1 in syngeneic C3H/He mice.

Authors:  T Arika; K Amemiya; K Nomoto
Journal:  Biotherapy       Date:  1992

4.  Mutagenic responses of thirteen anticancer drugs on mutation induction at multiple genetic loci and on sister chromatid exchanges in Chinese hamster ovary cells.

Authors:  B Singh; R S Gupta
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

5.  Increased mutation frequency following treatment with cancer chemotherapy.

Authors:  J L Dempsey; R S Seshadri; A A Morley
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

6.  Inhibition of mitomycin C-induced sister-chromatid exchanges in mouse bone marrow cells by the immunopotentiators Krestin and Lentinan.

Authors:  J Hasegawa; M Hosokawa; F Okada; H Kobayashi
Journal:  Mutat Res       Date:  1989-05       Impact factor: 2.433

7.  The mutagenic and carcinogenic properties of three second generation antitumour platinum compounds: a comparison with cisplatin.

Authors:  R Chibber; M J Ord
Journal:  Eur J Cancer Clin Oncol       Date:  1989-01

8.  Prediction of in vivo tumor response to chemotherapeutic agents by the in vitro sister chromatid exchange assay.

Authors:  P J Tofilon; I Basic; L Milas
Journal:  Cancer Res       Date:  1985-05       Impact factor: 12.701

9.  Cooperative role of T lymphocytes and macrophages in anti-tumor activity of mice pretreated with schizophyllan (SPG).

Authors:  M Suzuki; T Arika; K Amemiya; M Fujiwara
Journal:  Jpn J Exp Med       Date:  1982-04

10.  Clinical evaluation of schizophyllan combined with irradiation in patients with cervical cancer. A randomized controlled study.

Authors:  K Okamura; M Suzuki; T Chihara; A Fujiwara; T Fukuda; S Goto; K Ichinohe; S Jimi; T Kasamatsu; N Kawai
Journal:  Cancer       Date:  1986-08-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.